This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Hold Myriad Genetics Stock in Your Portfolio Right Now?
by Zacks Equity Research
MYGN sees growth in oncology and women's health testing, but GeneSight coverage loss clouds the near-term outlook.
Should You Add QIAGEN Stock to Your Portfolio for Now?
by Zacks Equity Research
QGEN rides on test menu growth, strategic partnerships, and strong solvency, despite macro and market headwinds.
Should You Continue to Hold Prestige Consumer Stock in Your Portfolio?
by Zacks Equity Research
PBH rides strong on e-commerce gains and brand innovations, but debt load and forex risks cast a shadow on future growth.
Bruker Stock Set to Gain From Acquisition of Austria's biocrates
by Zacks Equity Research
BRKR strengthens its MS-based metabolomics platform with the biocrates deal, boosting investor sentiment.
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
ECL Stock Gains Following Latest Launch to Boost Data Center Cooling
by Zacks Equity Research
Ecolab's 3D TRASAR technology expands its cooling solutions, aiming to optimize data centers and cut resource demand.
Should You Continue to Hold EXAS Sciences Stock in Your Portfolio?
by Zacks Equity Research
EXAS rides on strong Cologuard and Oncotype DX growth, but rising costs and high debt may test its staying power.
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EUSA
HIMS Stock Falls Despite Latest Deal to Expand International Footprint
by Zacks Equity Research
Hims & Hers is set to acquire ZAVA to launch in Germany, France and Ireland, deepening its personalized digital health push.
Should You Continue to Hold Labcorp Stock in Your Portfolio?
by Zacks Equity Research
LH's growth focus and financial strength look promising, but can it navigate rising competition and macro headwinds?
QGEN Stock to Gain From Expanding Oncology Portfolio via New Alliances
by Zacks Equity Research
QIAGEN expands the oncology portfolio with new MRD testing alliances, setting the stage for personalized cancer care and stock growth.
Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Cencora (COR) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
Charles River Stock May Gain From Extended CHDI Research Deal on HD
by Zacks Equity Research
CRL and CHDI Foundation extend their Huntington's disease partnership, boosting integration and global flexibility in drug discovery.
COO Q2 Earnings Beat, 2025 Sales Outlook Tightened, Stock Down
by Zacks Equity Research
COO's fiscal Q2 earnings and sales beat market expectations on the back of strong growth. Improvement in operating margin bodes well.
Here's Why You Should Add Cencora Stock to Your Portfolio Now
by Zacks Equity Research
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Reasons to Retain The Cooper Companies Stock in Your Portfolio Now
by Zacks Equity Research
COO benefits from the strength in its business segments. Its acquisitions are likely to drive the top line. However, a rise in selling, general and administrative expenses is concerning.
Hims & Hers Stock Falls Despite the Latest Wegovy Availability Offer
by Zacks Equity Research
HIMS launches six-month Wegovy access at $549/month, aiming to expand affordable obesity care with holistic weight loss solutions.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Beat the Market the Zacks Way: GE Aerospace, Monster Beverage, Cencora in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
by Zacks Equity Research
CNMD stock rides high on strong recurring revenues, margin gains, and surgical product growth despite supply and cybersecurity challenges.
RVTY Stock Falls Despite the Latest Launch of Automated Instrument
by Zacks Equity Research
Revvity unveils IDS i20, a fully automated immunodiagnostics platform designed to enhance lab efficiency and expand specialty testing.
Should iShares Russell Mid-Cap Growth ETF (IWP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWP
Here's Why Investors Should Consider Retaining Danaher Stock Now
by Zacks Equity Research
DHR gains from strength across its businesses, acquired assets and shareholder-friendly policies. High long-term debt remains concerning.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
by Zacks Equity Research
Sector ETF report for RSPH
MMSI Stock Gains Following Latest Merger to Boost Hemostasis Portfolio
by Zacks Equity Research
Merit Medical aims to provide an additional effective solution that complements a wide range of percutaneous procedures, including interventional radiology and cardiology.